Trial Profile
Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary) ; Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 16 Feb 2022 Planned End Date changed to 8 Jan 2022.
- 16 Feb 2022 Status changed from not stated to recruiting.
- 21 Sep 2018 New trial record